The IPO market is expected to remain active in the week ahead with nine IPOs scheduled to raise $2.7 billion.
Canadian digital service provider TELUS International (TIXT) plans to raise $800 million at a $6.4 billion market cap. The...read more
In a staggering start to 2021, two biotechs and 28 SPACs raised over $7.1 billion in the first week of the new year. Activity should remain high as new filings continued to flood the IPO pipeline. Chinese cancer biotech ...read more
Gracell Biotechnologies, a Phase 1 Chinese biotech developing CAR-T cell therapies for cancer, raised $209 million by offering 11 million ADSs at $19, above the range of $16 to $18. The company originally planned to offer 8.8 million ADSs before increasing the...read more
Gracell Biotechnologies, a Phase 1 Chinese biotech developing CAR-T cell therapies for cancer, raised the proposed deal size for its upcoming IPO on Thursday. The Suzhou, China-based company now plans to raise $187 million by offering 11 million ADSs at a...read more
US IPO Week Ahead: Canadian IT and German chemicals lead a diverse 9 IPO week
The IPO market is expected to remain active in the week ahead with nine IPOs scheduled to raise $2.7 billion. Canadian digital service provider TELUS International (TIXT) plans to raise $800 million at a $6.4 billion market cap. The...read more
US IPO Weekly Recap: The new year kicks off with 2 biotech IPOs and a tidal wave of SPACs
In a staggering start to 2021, two biotechs and 28 SPACs raised over $7.1 billion in the first week of the new year. Activity should remain high as new filings continued to flood the IPO pipeline. Chinese cancer biotech ...read more
Chinese cancer biotech Gracell Biotechnologies prices US IPO above the range at $19
Gracell Biotechnologies, a Phase 1 Chinese biotech developing CAR-T cell therapies for cancer, raised $209 million by offering 11 million ADSs at $19, above the range of $16 to $18. The company originally planned to offer 8.8 million ADSs before increasing the...read more
Chinese cancer biotech Gracell Biotechnologies increases deal size by 25% ahead of $187 million US IPO
Gracell Biotechnologies, a Phase 1 Chinese biotech developing CAR-T cell therapies for cancer, raised the proposed deal size for its upcoming IPO on Thursday. The Suzhou, China-based company now plans to raise $187 million by offering 11 million ADSs at a...read more